{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:30:19Z","timestamp":1793107819412,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T00:00:00Z","timestamp":1498176000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003670","name":"National Evidence-based Healthcare Collaborating Agency","doi-asserted-by":"publisher","award":["NA2015-001"],"award-info":[{"award-number":["NA2015-001"]}],"id":[{"id":"10.13039\/501100003670","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s10096-017-3031-7","type":"journal-article","created":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T23:47:56Z","timestamp":1498175276000},"page":"2093-2100","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-\u03b2-lactamase producing Escherichia coli and Klebisella pneumoniae definitively treated with carbapenems"],"prefix":"10.1007","volume":"36","author":[{"given":"E.-J.","family":"Joo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. A.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. R.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-y.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-K.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-H.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. R.","family":"Peck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,23]]},"reference":[{"issue":"7","key":"3031_CR1","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3346\/jkms.2013.28.7.998","volume":"28","author":"CI Kang","year":"2013","unstructured":"Kang CI, Cha MK, Kim SH, Ko KS, Wi YM, Chung DR, Peck KR, Lee NY, Song JH (2013) Clinical and molecular epidemiology of community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli over a 6-year period. J Korean Med Sci 28(7):998\u20131004","journal-title":"J Korean Med Sci"},{"issue":"14","key":"3031_CR2","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1001\/jama.2015.12480","volume":"314","author":"AY Guh","year":"2015","unstructured":"Guh AY, Bulens SN, Mu Y, Jacob JT, Reno J, Scott J, Wilson LE, Vaeth E, Lynfield R, Shaw KM, Vagnone PM, Bamberg WM, Janelle SJ, Dumyati G, Concannon C, Beldavs Z, Cunningham M, Cassidy PM, Phipps EC, Kenslow N, Travis T, Lonsway D, Rasheed JK, Limbago BM, Kallen AJ (2015) Epidemiology of Carbapenem-resistant Enterobacteriaceae in 7 US communities, 2012-2013. JAMA 314(14):1479\u20131487","journal-title":"JAMA"},{"issue":"12","key":"3031_CR3","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1128\/AAC.48.12.4574-4581.2004","volume":"48","author":"CI Kang","year":"2004","unstructured":"Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW (2004) Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 48(12):4574\u20134581","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"3031_CR4","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1128\/AAC.01509-06","volume":"51","author":"M Tumbarello","year":"2007","unstructured":"Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, Citton R, D\u2019Inzeo T, Fadda G, Cauda R, Spanu T (2007) Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 51(6):1987\u20131994","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"3031_CR5","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1128\/AAC.00063-08","volume":"52","author":"M Tumbarello","year":"2008","unstructured":"Tumbarello M, Sali M, Trecarichi EM, Leone F, Rossi M, Fiori B, De Pascale G, D\u2019Inzeo T, Sanguinetti M, Fadda G, Cauda R, Spanu T (2008) Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob Agents Chemother 52(9):3244\u20133252","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"3031_CR6","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s15010-011-0201-x","volume":"39","author":"FG Rosa De","year":"2011","unstructured":"De Rosa FG, Pagani N, Fossati L, Raviolo S, Cometto C, Cavallerio P, Parlato C, Guglielmi E, Serra R, Di Perri G (2011) The effect of inappropriate therapy on bacteremia by ESBL-producing bacteria. Infection 39(6):555\u2013561","journal-title":"Infection"},{"issue":"7","key":"3031_CR7","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1128\/AAC.01523-12","volume":"57","author":"FN Frakking","year":"2013","unstructured":"Frakking FN, Rottier WC, Dorigo-Zetsma JW, van Hattem JM, van Hees BC, Kluytmans JA, Lutgens SP, Prins JM, Thijsen SF, Verbon A, Vlaminckx BJ, Cohen Stuart JW, Leverstein-van Hall MA, Bonten MJ (2013) Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-beta-lactamase-producing bacteria. Antimicrob Agents Chemother 57(7):3092\u20133099","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"3031_CR8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3109\/00365548.2013.775479","volume":"45","author":"CI Kang","year":"2013","unstructured":"Kang CI, Wi YM, Ko KS, Chung DR, Peck KR, Lee NY, Song JH (2013) Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy. Scand J Infect dis 45(7):519\u2013525","journal-title":"Scand J Infect dis"},{"issue":"5","key":"3031_CR9","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic dis 40(5):373\u2013383","journal-title":"J Chronic dis"},{"issue":"10","key":"3031_CR10","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","volume":"13","author":"WA Knaus","year":"1985","unstructured":"Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care med 13(10):818\u2013829","journal-title":"Crit Care med"},{"key":"3031_CR11","volume-title":"Performance standards for antimicrobial susceptibility testing: 24th informational supplement CLSI document M100\u201324","author":"Clinical and Laboratory Standards Institue (CLSI)","year":"2014","unstructured":"Clinical and Laboratory Standards Institue (CLSI) (2014) Performance standards for antimicrobial susceptibility testing: 24th informational supplement CLSI document M100\u201324. CLSI, Wayne, PA"},{"issue":"3","key":"3031_CR12","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1001\/archinte.165.3.308","volume":"165","author":"JR McDonald","year":"2005","unstructured":"McDonald JR, Friedman ND, Stout JE, Sexton DJ, Kaye KS (2005) Risk factors for ineffective therapy in patients with bloodstream infection. Arch Intern med 165(3):308\u2013313","journal-title":"Arch Intern med"},{"issue":"10","key":"3031_CR13","doi-asserted-by":"crossref","first-page":"791","DOI":"10.7326\/0003-4819-137-10-200211190-00007","volume":"137","author":"ND Friedman","year":"2002","unstructured":"Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W, Clark C, MacFarquhar J, Walton AL, Reller LB, Sexton DJ (2002) Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 137(10):791\u2013797","journal-title":"Ann Intern Med"},{"issue":"1","key":"3031_CR14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1086\/649537","volume":"50","author":"J Rodriguez-Bano","year":"2010","unstructured":"Rodriguez-Bano J, Picon E, Gijon P, Hernandez JR, Ruiz M, Pena C, Almela M, Almirante B, Grill F, Colomina J, Gimenez M, Oliver A, Horcajada JP, Navarro G, Coloma A, Pascual A (2010) Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 50(1):40\u201348","journal-title":"Clin Infect Dis"},{"issue":"5","key":"3031_CR15","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3947\/ic.2010.42.5.280","volume":"42","author":"HS Cheong","year":"2010","unstructured":"Cheong HS, Ko KS, Kang CI, Chung DR, Peck KR, Song JH (2010) Prevalence of extended-spectrum beta-lactamase among Enterobacteriacae blood isolates with inducible AmpC beta-lactamase. Infect Chemother 42(5):280\u2013284","journal-title":"Infect Chemother"},{"issue":"4","key":"3031_CR16","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/jac\/dkt450","volume":"69","author":"HM Nguyen","year":"2014","unstructured":"Nguyen HM, Shier KL, Graber CJ (2014) Determining a clinical framework for use of cefepime and beta-lactam\/beta-lactamase inhibitors in the treatment of infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 69(4):871\u2013880","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"3031_CR17","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/cid\/cit017","volume":"56","author":"MN Dudley","year":"2013","unstructured":"Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ, Jones RN (2013) Background and rationale for revised clinical and laboratory standards institute interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas Aeruginosa: I. Cephalosporins and Aztreonam. Clin Infect Dis 56(9):1301\u20131309","journal-title":"Clin Infect Dis"},{"issue":"6","key":"3031_CR18","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1128\/AAC.00381-05","volume":"50","author":"PJ Gavin","year":"2006","unstructured":"Gavin PJ, Suseno MT, Thomson RB Jr, Gaydos JM, Pierson CL, Halstead DC, Aslanzadeh J, Brecher S, Rotstein C, Brossette SE, Peterson LR (2006) Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother 50(6):2244\u20132247","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"3031_CR19","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1128\/AAC.47.5.1643-1646.2003","volume":"47","author":"PG Ambrose","year":"2003","unstructured":"Ambrose PG, Bhavnani SM, Jones RN (2003) Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program. Antimicrob Agents Chemother 47(5):1643\u20131646","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"3031_CR20","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/cid\/civ003","volume":"60","author":"PD Tamma","year":"2015","unstructured":"Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, Avdic E, Cosgrove SE (2015) Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia. Clin Infect Dis 60(9):1319\u20131325","journal-title":"Clin Infect Dis"},{"issue":"12","key":"3031_CR21","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/jac\/dks301","volume":"67","author":"KZ Vardakas","year":"2012","unstructured":"Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME (2012) Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 67(12):2793\u20132803","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"3031_CR22","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1086\/322667","volume":"33","author":"E Lautenbach","year":"2001","unstructured":"Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO (2001) Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 33(8):1288\u20131294","journal-title":"Clin Infect Dis"},{"issue":"12","key":"3031_CR23","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1086\/668443","volume":"33","author":"JH Han","year":"2012","unstructured":"Han JH, Nachamkin I, Zaoutis TE, Coffin SE, Linkin DR, Fishman NO, Weiner MG, Hu B, Tolomeo P, Lautenbach E (2012) Risk factors for gastrointestinal tract colonization with extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella species in hospitalized patients. Infect Control Hosp Epidemiol 33(12):1242\u20131245","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"3","key":"3031_CR24","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ijantimicag.2010.05.009","volume":"36","author":"CI Kang","year":"2010","unstructured":"Kang CI, Song JH, Chung DR, Peck KR, Ko KS, Yeom JS, Ki HK, Son JS, Lee SS, Kim YS, Jung SI, Kim SW, Chang HH, Ryu SY, Kwon KT, Lee H, Moon C, Shin SY (2010) Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli. Int J Antimicrob Agents 36(3):284\u2013287","journal-title":"Int J Antimicrob Agents"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-017-3031-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-017-3031-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-017-3031-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T23:15:50Z","timestamp":1750374950000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-017-3031-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,23]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["3031"],"URL":"https:\/\/doi.org\/10.1007\/s10096-017-3031-7","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,23]]}}}